Management of Hepatitis C in Patients with Chronic Kidney Disease

Initial Assessment and Treatment Considerations

All patients with chronic kidney disease (CKD) and Hepatitis C virus (HCV) infection should be evaluated for direct-acting antiviral (DAA) therapy, with the specific regimen choice based on renal function, comorbidities, and drug interactions, as recommended by the Kidney International guidelines 1
The initial assessment should include confirmation of the diagnosis with nucleic acid testing (NAT) and assessment of liver fibrosis using non-invasive methods, such as FibroScan or serum biomarkers, as suggested by the Kidney International guidelines 2
Patients with CKD III should be monitored closely for signs of portal hypertension and worsening kidney function, as HCV can accelerate CKD progression, according to the Kidney International guidelines 2

The treatment approach for HCV in patients with CKD III should be individualized based on exact GFR, with consideration of ribavirin contraindication if creatinine clearance is less than 50 mL/min, as recommended by the Hepatology guidelines 5, 3
Direct-acting antivirals (DAAs) are the standard of care, with recommended regimens including Glecaprevir/Pibrentasvir for 8 weeks (all genotypes) and Grazoprevir/Elbasvir for 12 weeks (genotypes 1a, 1b, 4), as suggested by the Kidney International guidelines 1

Regular assessment of liver function tests (ALT, AST) and monitoring of kidney function for potential worsening are essential during treatment, as recommended by the Kidney International guidelines 1, 2
Patients should be screened for hepatitis A and B viruses, HIV, and other comorbidities, and addressed through vaccination, counseling, and management of modifiable risk factors, such as smoking cessation, diabetes management, and blood pressure control, as suggested by the Hepatology guidelines 2, 4

Avoid assuming normal ALT means absence of significant liver disease, as patients with renal disease may have significant fibrosis despite normal ALT values, according to the Hepatology guidelines 5, 6
Recognize that fatigue may be multifactorial, related to HCV, CKD, hypothyroidism, or depression, and that some medications for comorbidities may require dose adjustment based on both liver and kidney function, as recommended by the Kidney International guidelines 4, 1